Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals

被引：0
|
作者：
Chhatwal, Jag [1 ,2 ,3 ,4 ]
Chen, Qiushi [4 ]
Bethea, Emily [1 ,2 ]
Ayer, Turgay [5 ]
Zhuo, Yueran [4 ]
Hur, Chin [1 ,2 ]
Spaulding, Anne [6 ]
Kanwal, Fasiha [7 ]
机构：
[1] Massachusetts Gen Hosp, Liver Ctr, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Gastrointestinal Div, Boston, MA 02114 USA
[3] Harvard Med Sch, Boston, MA USA
[4] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA
[5] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA
[6] Rollins Sch Publ Hlth, Druid Hills, GA USA
[7] Michael E Debakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1613
引用
收藏
页码：918A / 919A
页数：2
相关论文
共 50 条
  • [41] Direct-acting antivirals for children and adolescents with chronic hepatitis C
    Indolfi, Giuseppe
    Serranti, Daniele
    Resti, Massimo
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (04): : 298 - 304
  • [42] Safety of direct-acting antivirals in the treatment of chronic hepatitis C
    Ridruejo, Ezequiel
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (03) : 307 - 319
  • [43] Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
    Gountas, Ilias
    Sypsa, Vana
    Papatheodoridis, George
    Souliotis, Kyriakos
    Athanasakis, Kostas
    Razavi, Homie
    Hatzakis, Angelos
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (11) : 1327 - 1340
  • [44] Disparities in hepatitis C treatment in the era of direct-acting antivirals among Arizona Medicaid beneficiaries
    Song, Hyun Jin
    Chang, Ching-Yuan
    Jiang, Xinyi
    Wilson, Debbie L.
    Lo-Ciganic, Wei-Hsuan
    Park, Haesuk
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 39 - 39
  • [45] Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals
    Fukumoto, Tsuyoshi
    Minami, Tatsuya
    Moriyama, Makoto
    Yamada, Tomoharu
    Wake, Taijiro
    Kinoshita, Mizuki Nishibatake
    Fujiwara, Naoto
    Nakagomi, Ryo
    Nakatsuka, Takuma
    Sato, Masaya
    Enooku, Kenichiro
    Nakagawa, Hayato
    Fujishiro, Mitsuhiro
    Shiina, Shuichiro
    Koike, Kazuhiko
    Tateishi, Ryosuke
    HEPATOLOGY COMMUNICATIONS, 2022, 6 (09) : 2496 - 2512
  • [46] Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals
    Yan Huang
    Ming-Hui Li
    Min Hou
    Yao Xie
    Hepatobiliary&PancreaticDiseasesInternational, 2017, 16 (05) : 470 - 479
  • [47] Management of Hepatitis C Virus in HIV-Infected Patients in the Era of Direct-Acting Antivirals
    Zeremski, Marija
    Martinez, Anthony D.
    Talal, Andrew H.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (06) : 880 - 882
  • [48] HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals
    Kian Bichoupan
    Douglas T. Dieterich
    Valérie Martel-Laferrière
    Current HIV/AIDS Reports, 2014, 11 : 241 - 249
  • [49] Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
    Comarmond, Cloe
    Cacoub, Patrice
    Saadoun, David
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [50] Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
    Trinks, Julieta
    Caputo, Mariela
    Hulaniuk, Maria L.
    Corach, Daniel
    Flichman, Diego
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 : 79 - 91
12345